| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | Sell |
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203
Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
0
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
http://www.zacks.com/stock/news/352788/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth?cid=CS-ZC-FT-352788
Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
0
Stock Market News For Feb 7, 2019
http://www.zacks.com/stock/news/352868/stock-market-news-for-feb-7-2019?cid=CS-ZC--352868
Feb 07, 2019 - U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.
0
Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript
https://www.fool.com/investing/2019/02/06/eli-lilly-co-lly-q4-2019-earnings-conference-call.aspx?source=iedfolrf0000001
Feb 06, 2019 - LLY earnings call for the period ending December 31, 2018.
0
Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare
Feb 06, 2019 -
0
Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View
http://www.zacks.com/stock/news/352407/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view?cid=CS-ZC-FT-352407
Feb 06, 2019 - Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.
0
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085
Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
0
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
http://www.zacks.com/stock/news/352006/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines?cid=CS-ZC-FT-352006
Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
0
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133
Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
0
Roche Submits sBLA to FDA for Label Expansion of Kadcyla
http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-ZC-FT-352051
Feb 05, 2019 - Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
0